Antinociceptive Effects of Transcytosed Botulinum Neurotoxin Type A on Trigeminal Nociception in Rats

Overview

Journal Korean J Physiol Pharmacol

Specialty Pharmacology

Date 2015 Jul 15

PMID 26170739

Citations 14

Authors

Hye-Jin Kim

Geun-Woo Lee

Min-Ji Kim

Kui-Ye Yang

Seong-Taek Kim

Yong-Cheol Bae

Dong-Kuk Ahn

Affiliations

Soon will be listed here.

Abstract

We examined the effects of peripherally or centrally administered botulinum neurotoxin type A (BoNT-A) on orofacial inflammatory pain to evaluate the antinociceptive effect of BoNT-A and its underlying mechanisms. The experiments were carried out on male Sprague-Dawley rats. Subcutaneous (3 U/kg) or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced nociceptive response in the second phase. Both subcutaneous (1 or 3 U/kg) and intracisternal (0.3 or 1 U/kg) injection of BoNT-A increased the latency of head withdrawal response in the complete Freund's adjuvant (CFA)-treated rats. Intracisternal administration of N-methyl-D-aspartate (NMDA) evoked nociceptive behavior via the activation of trigeminal neurons, which was attenuated by the subcutaneous or intracisternal injection of BoNT-A. Intracisternal injection of NMDA up-regulated c-Fos expression in the trigeminal neurons of the medullary dorsal horn. Subcutaneous (3 U/kg) or intracisternal (1 U/kg) administration of BoNT-A significantly reduced the number of c-Fos immunoreactive neurons in the NMDA-treated rats. These results suggest that the central antinociceptive effects the peripherally or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal neurons. Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the treatment of orofacial chronic pain conditions.

Citing Articles

Blockade of Piezo2 Pathway Attenuates Inflammatory and Neuropathic Pain in the Orofacial Area.

Jo M, Son J, Kim Y, Ju J, Park M, Lee M Pain Res Manag. 2024; 2024:9179928.

PMID: 39372838 PMC: 11452243. DOI: 10.1155/2024/9179928.

Changes in the analgesic mechanism of oxytocin can contribute to hyperalgesia in Parkinson's disease model rats.

Usami N, Maegawa H, Hayashi M, Kudo C, Niwa H PLoS One. 2024; 19(8):e0300081.

PMID: 39163355 PMC: 11335116. DOI: 10.1371/journal.pone.0300081.

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.

Rasetti-Escargueil C, Palea S Toxins (Basel). 2024; 16(6).

PMID: 38922155 PMC: 11209287. DOI: 10.3390/toxins16060261.

Action of Botulinum Neurotoxin E Type in Experimental Epilepsies.

Antonucci F, Bozzi Y Toxins (Basel). 2023; 15(9).

PMID: 37755976 PMC: 10536604. DOI: 10.3390/toxins15090550.

TNF-α-Mediated RIPK1 Pathway Participates in the Development of Trigeminal Neuropathic Pain in Rats.

Son J, Ju J, Kim Y, Ahn D Int J Mol Sci. 2022; 23(1).

PMID: 35008931 PMC: 8745573. DOI: 10.3390/ijms23010506.

References

Ahnert-Hilger G, Bigalke H . Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol. 1995; 46(1):83-96. DOI: 10.1016/0301-0082(95)00003-e. View

Smuts J, Schultz D, Barnard A . Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004; 44(8):801-5. DOI: 10.1111/j.1526-4610.2004.04148.x. View

Hua Y, Scheller R . Three SNARE complexes cooperate to mediate membrane fusion. Proc Natl Acad Sci U S A. 2001; 98(14):8065-70. PMC: 35468. DOI: 10.1073/pnas.131214798. View

Wang X, Zhang Z, Bains R, Mokha S . Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002; 98(1-2):27-35. DOI: 10.1016/s0304-3959(01)00464-x. View

Welch M, Purkiss J, Foster K . Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38(2):245-58. DOI: 10.1016/s0041-0101(99)00153-1. View

Rizo J, Sudhof T . Mechanics of membrane fusion. Nat Struct Biol. 1998; 5(10):839-42. DOI: 10.1038/2280. View

Chang K, Bai S, Lee H, Lee B . Effects of acupuncture stimulation at different acupoints on formalin-induced pain in rats. Korean J Physiol Pharmacol. 2014; 18(2):121-7. PMC: 3994298. DOI: 10.4196/kjpp.2014.18.2.121. View

Schiavo G, Matteoli M, Montecucco C . Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80(2):717-66. DOI: 10.1152/physrev.2000.80.2.717. View

Zhang K, Wang X, Peterson A, Chen W, Mokha S . alpha2-adrenoceptors modulate NMDA-evoked responses of neurons in superficial and deeper dorsal horn of the medulla. J Neurophysiol. 1998; 80(4):2210-4. DOI: 10.1152/jn.1998.80.4.2210. View

10.

Cui M, Khanijou S, Rubino J, Aoki K . Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004; 107(1-2):125-33. DOI: 10.1016/j.pain.2003.10.008. View

11.

Yaksh T, Rudy T . Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 1976; 17(6):1031-6. DOI: 10.1016/0031-9384(76)90029-9. View

12.

Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W . Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009; 159(4):1422-9. DOI: 10.1016/j.neuroscience.2009.01.066. View

13.

Clavelou P, Pajot J, Dallel R, Raboisson P . Application of the formalin test to the study of orofacial pain in the rat. Neurosci Lett. 1989; 103(3):349-53. DOI: 10.1016/0304-3940(89)90125-0. View

14.

de Paiva A, Poulain B, Lawrence G, Shone C, Tauc L, Dolly J . A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem. 1993; 268(28):20838-44. View

15.

Yang G, Woo Y, Park M, Bae Y, Ahn D, Bonfa E . Intracisternal administration of NR2 antagonists attenuates facial formalin-induced nociceptive behavior in rats. J Orofac Pain. 2010; 24(2):203-11. View

16.

Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z . Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010; 633(1-3):10-4. DOI: 10.1016/j.ejphar.2010.01.020. View

17.

Ahn D, Lee S, Han S, Ju J, Yang G, Lee M . Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain. 2009; 146(1-2):114-20. DOI: 10.1016/j.pain.2009.07.012. View

18.

Bach-Rojecky L, Lackovic Z . Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005; 46(2):201-8. View

19.

Gobel H, Heinze A, Heinze-Kuhn K, Austermann K . Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91(3):195-199. DOI: 10.1016/S0304-3959(01)00292-5. View

20.

Foster L, Clapp L, Erickson M, Jabbari B . Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56(10):1290-3. DOI: 10.1212/wnl.56.10.1290. View